Unraveling the molecular regulation of biofilm underlying effect of chronic disease medications.

IF 1.5 4区 生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Bayan Taha Majid, Suha Ali Hussein, Shwan Kamal Rachid
{"title":"Unraveling the molecular regulation of biofilm underlying effect of chronic disease medications.","authors":"Bayan Taha Majid, Suha Ali Hussein, Shwan Kamal Rachid","doi":"10.14715/cmb/2024.70.7.3","DOIUrl":null,"url":null,"abstract":"<p><p>A biofilm is a complex microbial structure that promotes the progression of persistent infections, particularly in nosocomial settings via indwelling medical devices. Conventional antibiotics are often ineffective treatments for biofilms; hence, it is crucial to investigate or design non-antibiotic antibiofilm compounds that can successfully reduce and eradicate biofilm-related infections. This study was an attempt to repurpose chronic disease medications of the antihypertensive and antilipidemic drug classes, including candesartan cilexetil (CC) and ursodeoxycholic acid (UDCA), respectively, to be used as antibiofilm agents against the two infectious pathogens Staphylococcus aureus and Enterococcus faecalis. Crystal violet (CV) staining assay was used to evaluate the antibiofilm activity of the drugs. Real-time polymerase chain reaction (RT-PCR) was performed to determine the transcription levels of the biofilm-related genes (icaA and icaR in S. aureus and fsrC and gelE in E. faecalis) following treatment with different concentrations of CC and UDCA. we found that a concentration of greater than 1.5 µg/ml of CC significantly (p < 0.005) inhibited the biofilm formation of both bacterial isolates, and a concentration of greater than 50 µg/ml of UDCA significantly (p < 0.005) inhibited the biofilm formation of both bacterial isolates. Interestingly, the mRNA expression levels of biofilm-related genes were decreased in the two bacterial isolates at concentrations that were lower than the human pharmaceutical daily doses.</p>","PeriodicalId":9802,"journal":{"name":"Cellular and molecular biology","volume":"70 7","pages":"15-21"},"PeriodicalIF":1.5000,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular and molecular biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.14715/cmb/2024.70.7.3","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A biofilm is a complex microbial structure that promotes the progression of persistent infections, particularly in nosocomial settings via indwelling medical devices. Conventional antibiotics are often ineffective treatments for biofilms; hence, it is crucial to investigate or design non-antibiotic antibiofilm compounds that can successfully reduce and eradicate biofilm-related infections. This study was an attempt to repurpose chronic disease medications of the antihypertensive and antilipidemic drug classes, including candesartan cilexetil (CC) and ursodeoxycholic acid (UDCA), respectively, to be used as antibiofilm agents against the two infectious pathogens Staphylococcus aureus and Enterococcus faecalis. Crystal violet (CV) staining assay was used to evaluate the antibiofilm activity of the drugs. Real-time polymerase chain reaction (RT-PCR) was performed to determine the transcription levels of the biofilm-related genes (icaA and icaR in S. aureus and fsrC and gelE in E. faecalis) following treatment with different concentrations of CC and UDCA. we found that a concentration of greater than 1.5 µg/ml of CC significantly (p < 0.005) inhibited the biofilm formation of both bacterial isolates, and a concentration of greater than 50 µg/ml of UDCA significantly (p < 0.005) inhibited the biofilm formation of both bacterial isolates. Interestingly, the mRNA expression levels of biofilm-related genes were decreased in the two bacterial isolates at concentrations that were lower than the human pharmaceutical daily doses.

揭示慢性病药物作用背后的生物膜分子调控。
生物膜是一种复杂的微生物结构,可促进持续性感染的发展,尤其是在通过留置医疗器械造成的非医院环境中。传统抗生素往往无法有效治疗生物膜,因此,研究或设计能够成功减少和根除生物膜相关感染的非抗生素抗生物膜化合物至关重要。本研究试图重新利用抗高血压和抗血脂类慢性病药物,包括坎地沙坦西来替酯(CC)和熊去氧胆酸(UDCA),将其用作抗生物膜剂,以对抗金黄色葡萄球菌和粪肠球菌这两种感染性病原体。晶体紫(CV)染色法用于评估药物的抗生物膜活性。在使用不同浓度的 CC 和 UDCA 处理后,进行了实时聚合酶链反应(RT-PCR)以确定生物膜相关基因(金黄色葡萄球菌中的 icaA 和 icaR 以及粪肠球菌中的 fsrC 和 gelE)的转录水平。我们发现,浓度大于 1.5 µg/ml 的 CC 能显著抑制两种细菌分离物的生物膜形成(p < 0.005),而浓度大于 50 µg/ml 的 UDCA 能显著抑制两种细菌分离物的生物膜形成(p < 0.005)。有趣的是,当浓度低于人体每日用药剂量时,两种细菌分离物中生物膜相关基因的 mRNA 表达水平都有所下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cellular and molecular biology
Cellular and molecular biology 生物-生化与分子生物学
CiteScore
1.60
自引率
12.50%
发文量
331
期刊介绍: Cellular and Molecular Biology publishes original articles, reviews, short communications, methods, meta-analysis notes, letters to editor and comments in the interdisciplinary science of Cellular and Molecular Biology linking and integrating molecular biology, biophysics, biochemistry, enzymology, physiology and biotechnology in a dynamic cell and tissue biology environment, applied to human, animals, plants tissues as well to microbial and viral cells. The journal Cellular and Molecular Biology is therefore open to intense interdisciplinary exchanges in medical, dental, veterinary, pharmacological, botanical and biological researches for the demonstration of these multiple links.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信